anemia
Clinical studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in correcting the anemia of zidovudine-treated patients infected with human immunodeficiency virus with baseline serum erythropoietin levels of 500 U/L or less.
Clinical studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in correcting the <span class="disease" id="8250662-2-105-111">anemia</span> of zidovudine-treated patients infected with human immunodeficiency virus with baseline serum <span class="gene" id="8250662-2-206-220">erythropoietin</span> levels of 500 U/L or less.